Goldman Sachs has added UnitedHealth Group (UNH) to its U.S. conviction list, signaling strong confidence in the stock’s potential. As the largest health insurer in the U.S., UnitedHealth has faced significant volatility over the past 18 months, primarily due to unexpected costs in its Medicare Advantage plans. However, Goldman Sachs believes the company is nearing a turning point in its underwriting cycle, which could lead to improved profitability.
The investment bank’s bullish stance is supported by favorable developments, including higher-than-expected Medicare Advantage rate increases from the Centers for Medicare & Medicaid Services (CMS) and strategic exits from unprofitable markets. UnitedHealth’s valuation remains attractive, trading at 20.8 times forward earnings, below its historical average. Additionally, the company’s Optum unit is expected to see margin improvements, further bolstering growth prospects.
For market professionals, Goldman Sachs’ endorsement of UnitedHealth suggests a compelling buying opportunity, particularly as the stock could serve as a defensive play amid broader market uncertainties.
Source: fool.com